Skip to main content

Author: Customer Service

Airlife Gases Acquires Control of Royal Helium Ltd.

PUNE, India, Nov. 29, 2025 (GLOBE NEWSWIRE) — Airlife Gases Private Limited (“AirLife”) is pleased to announce that it has completed the acquisition, through a wholly-owned subsidiary, of a total of 79,901,328 Class A common voting shares (the “Common Shares”) of Royal Helium Ltd. (“Royal Helium”) and 4,000,000 share purchase warrants of Royal Helium (“Warrants”), representing approximately 52.9% of the issued and outstanding Common Shares on a fully-diluted basis. Each Warrant can be exercised to purchase one Common Share at a price of $0.65 per share for a period of 36 months. Royal Helium is an exploration, production and infrastructure company with a primary focus on the development of helium and associated gases. Royal Helium’s extensive footprint includes prospective helium permits and leases across Southern Saskatchewan...

Continue reading

Volaris Completed EASA-Mandated A320 Inspections and Repairs with No Cancellations and Minimal Delays

MEXICO CITY, Nov. 29, 2025 (GLOBE NEWSWIRE) —  Controladora Vuela Compañía de Aviación, S.A.B. de C.V. (NYSE: VLRS and BMV: VOLAR) (“Volaris” or “the Company”), the ultra-low-cost carrier (ULCC) serving Mexico, the United States, Central and South America, announed today the successful completion of all inspections and repairs required under the Airworthiness directive issued last Friday by the European Union Aviation Safety Agency (EASA) on the official notification from Airbus (AOT Alert Operators Transmission) affecting approximately 6,000 A320-family aircraft worldwide. The directive addressed a flight-control software issue potentially influenced by solar flares, and in some cases required associated hardware checks. Volaris completed the full scope of work across its fleet without a single flight cancellation and with only...

Continue reading

Hotel101 Global Announces a Joint Venture with Definitive Binding Agreements Signed for the Development of Hotel101 in Milan, Italy

HOTEL101-MILAN IS SET TO HAVE APPROX. 429 ROOMS TO RISE IN A 1.4 HECTARE PRIME SITE AT SAN DONATO MILANESE, ABOUT A 7-MINUTE DRIVE TO THE MILAN LINATE AIRPORT HOTEL101-MILAN IS EXPECTED TO GENERATE EUR85.8 MILLION IN SALES REVENUE HOTEL101-MILAN IS SET TO BECOME THE SECOND HOTEL101 IN EUROPE, AND WITH ITS 1.4 HECTARE PRIME SITE AND APPROX. 429 ROOMS IS EXPECTED TO BE ONE OF THE TOP 3 LARGEST HOTELS IN THE METROPOLITAN CITY OF MILAN BY ROOMCOUNT(Site location of Hotel101-Milan, Italy set to have approx. 429 rooms) SINGAPORE, Nov. 29, 2025 (GLOBE NEWSWIRE) — Hotel101 Global Holdings Corp. (NASDAQ Ticker: HBNB) (“Hotel101” or “Hotel101 Global”), a leading asset-light, prop-tech hospitality platform pioneering a global standardized “condotel” business model listed on the Nasdaq Stock Exchange and a subsidiary of Philippine-listed...

Continue reading

MAAS Announces Change to the Board of Directors

CHENGDU, China, Nov. 28, 2025 (GLOBE NEWSWIRE) — Maase Inc. (NASDAQ: MAAS) (“MAAS” or the “Company”) today announced the appointment of Mr. Jingkai Li as a director and the chairman of the board of directors (the “Board”), effective November 28, 2025. Mr. Li succeeds Ms. Hong Suong Nguyen, who has resigned from her positions as the chairperson and a director of the Board for personal reasons, effective on the same date. Mr. Li holds an executive master degree in business administration from Macau University of Science and Technology. His appointment reflects the Board’s confidence in his profound management expertise, forward-looking investment vision, and extensive background in the green industry. Over more than a decade leading Guangxi Qinyuan Environmental Protection Co., Ltd., he successfully built a technology-driven, cross-regional...

Continue reading

Rakovina Therapeutics Announces Debentureholder Approval of Debenture Extension, Expiry of Warrant Incentive Program

VANCOUVER, British Columbia, Nov. 28, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, announces that further to its news release dated June 30, 2025, and in accordance with the terms of a debenture indenture (the “Indenture”) between the Company and Odyssey Trust Company as the debenture trustee (the “Debenture Trustee”) dated May 29, 2023, governing the 12.0% convertible debentures of the Company in the aggregate principal amount of $1,454,000.00 (the “Convertible Debentures“), holders (each, a “Debentureholder“) representing at least 66 2/3% of the outstanding principal of the Convertible Debentures have consented to the extension of the maturity date of the...

Continue reading

Algernon Closes Second Tranche of Private Placement Financing

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Nov. 28, 2025 (GLOBE NEWSWIRE) — Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, announces the closing of the second tranche (the “Second Tranche”) of its non-brokered private placement (the “Offering”), previously announced on November 6, 2025, with the first tranche closed on November 14, 2025. Gross proceeds from the Second Tranche totaled CAD $210,000 from the sale of 3,000,000 units (the “Units”) at an issue price of CAD $0.07 per Unit. The Company did not pay any cash finder’s fees pertaining to the Second Tranche of the Offering. The Company will use the proceeds of the Offering towards advancing its Alzheimer’s Disease (“AD”)...

Continue reading

Pharmacorp Rx Inc. Reports Q3 2025 Financial Results

SASKATOON, Saskatchewan, Nov. 28, 2025 (GLOBE NEWSWIRE) — PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) a growing national platform for pharmacist-led community pharmacy ownership, today reported its financial results for the three and nine months ended September 30, 2025. The third quarter reflected continued operational momentum, increased financial performance from individual pharmacy locations, driven by higher revenues, improved margins, better operating efficiencies, and disciplined progress on the Corporation’s national acquisition strategy. Following quarter-end, PharmaCorp completed the acquisitions of 3 pharmacies, 2 located in Western Canada and 1 located in Eastern Canada, building further scale and reinforcing the platform’s coast-to-coast ambitions. Q3 2025 Financial HighlightsRevenues are...

Continue reading

PharmaCorp Announces Executive Transition and New Director of Business Development

SASKATOON, Saskatchewan, Nov. 28, 2025 (GLOBE NEWSWIRE) — PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) today announced an executive transition in which Paul Dale has been appointed President and Chief Operating Officer, effective December 1, 2025, as Calvin LeRoux steps aside from the President role and assumes a one-year appointment as Strategic Advisor to the Chief Executive Officer. Mr. Dale has served as PharmaCorp’s Chief Operating Officer since its inception and will now take on broader leadership responsibilities as PharmaCorp advances its national expansion strategy. “Paul’s appointment reinforces the continuity of our operating model and our confidence in his leadership,” said Alan Simpson, Executive Chairman of PharmaCorp. “His experience managing complex retail organizations and his steady execution...

Continue reading

ThreeD Capital Inc. Releases Results For the Three months September 30, 2025

TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) — ThreeD Capital Inc. (“ThreeD” or the “Company”) (CSE:IDK / OTCQX:IDKFF) a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, is pleased to announce its unaudited quarterly results as at and for the three months September 30, 2025. As at September 30, 2025, the Company had cash, investments and digital assets of $26.5 million. As at September 30, 2025, net asset value per share was $0.31 as compared to $0.40 as at June 30, 2025. (See “Use of Non-GAAP Financial Measures” elsewhere) Financial Highlights for the three months ended September 30, 2025 with comparatives:     Operating Results September 30, 2025 September 30, 2024Net investment and digital assets losses $   (1,952,447) $   (118,701)Operating,...

Continue reading

Mondelēz Global LLC Conducts Limited Voluntary Recall of 1 SKU of RITZ Peanut Butter Cracker Sandwiches in New York, New Jersey, Pennsylvania, Georgia, Arkansas, Missouri, Oklahoma, and Alabama

EAST HANOVER, N.J., Nov. 28, 2025 (GLOBE NEWSWIRE) — Mondelēz Global LLC announced today a voluntary recall of 70 cases of RITZ Peanut Butter Cracker Sandwiches and sold in the following U.S. states: New York, New Jersey, Pennsylvania, Georgia, Arkansas, Missouri, Oklahoma, and Alabama. This recall is limited to 1 SKU and 2 Code Dates previously recalled in July. This action is not an expansion of that prior recall and is being conducted out of an abundance of caution. The affected cartons include individually wrapped packs that may be incorrectly labeled as Cheese variety even though the product may be a Peanut Butter variety. People who have an allergy or severe sensitivity to peanuts may risk serious or life-threatening allergic reactions by consuming this product. All outer cartons affected are labeled correctly and provide...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.